Centre Specialites Pharmaceutiques Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: Centre Specialites Pharmaceutiques Pharmaceutical Import Records from India — 3 Products, $7.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Centre Specialites Pharmaceutiques — Pharmaceutical Importer Profile (2026) | 3 Products, $7.3M Trade | TransData Nexus

Centre Specialites Pharmaceutiques

Pharmaceutical Importer · France · Diabetes & Endocrine Focus · $7.3M Total Trade · DGFT Verified

Centre Specialites Pharmaceutiques is a pharmaceutical importer based in France with a total trade value of $7.3M across 3 products in 3 therapeutic categories. Based on 158 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Centre Specialites Pharmaceutiques sources from 8 verified Indian suppliers, with Micro Labs Limited accounting for 74.6% of imports.

Centre Specialites Pharmaceutiques — Import Portfolio & Supplier Network

Centre Specialites Pharmaceutiques import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Centre Specialites Pharmaceutiques?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Micro Labs Limited	$19.5M	868	74.6%
Zydus Lifesciences Limited	$3.9M	323	14.8%
Cadila Healthcare Limited	$2.0M

What Formulations Does Centre Specialites Pharmaceutiques Import?

Formulation	Value	Ships
Metformine biogaran 1000 MG, coated	$537.9K	15
Metopimazine venipharm 7.5MG sans	$500.0K	10
Metformine bgr 500 MG coated tablet	$389.0K	8
Ebastine biogaran 10 MG comprimes	$350.0K	7
Diclofenac biogaran l.p.75MG(diclofenac	$350.0K	7
Ebastine biogaran 10MG orodispersible	$326.9K	7
Metformine biogaran 1000MG,coated	$313.1K	8
Solifenacine bgr 5MG comprime	$250.0K	5
Metformine bgr 850 MG coated	$242.8K	7
Metformine bgr 850 MG, coated	$212.9K	5
Pharma cefpod prox tablets 100MG france biogaran cefpodoxime proxetil 100MG 1boxx10 tabs others	$200.0K	4
Isalia 7.5MG sans sucre	$200.0K	4
Metformine bgr 850 MG coated tablet	$199.7K	5
Metformine biogaran 1000 MG coated	$192.9K	6
Metformine biogaran 1000MG,coated tablet(metformin hydrochloride tablets 1000MG) (Pack 6x15s) tax	$189.1K	6

Centre Specialites Pharmaceutiques imports 869 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Metformin	Diabetes & Endocrine	$5.9M	130	1.3%	12
2	Diclofenac	Analgesics & Antipyretics	$1.3M	26	0.4%	12
3	Atenolol	Cardiovascular	$100.0K	2	0.2%	13

Centre Specialites Pharmaceutiques imports 3 pharmaceutical products across 3 categories into France totaling $7.3M.

Centre Specialites Pharmaceutiques — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Centre Spécialités Pharmaceutiques (CSP) is a French import and export company specializing in the wholesale distribution of pharmaceutical products. Established in 1957, CSP is headquartered at 76 Avenue du Midi, Cournon-d'Auvergne, Auvergne, France. The company operates under the legal structure of a Société par Actions Simplifiée (SAS), a form of simplified joint-stock company in France. CSP employs between 500 and 999 individuals, reflecting its significant presence in the pharmaceutical distribution sector. (data-prospection.fr)

CSP plays a pivotal role in France's pharmaceutical supply chain by acting as a primary wholesaler and distributor. The company manages the storage, handling, and distribution of pharmaceutical products, ensuring that these products reach healthcare professionals and institutions across the country. This involves overseeing the logistics of pharmaceutical goods from production lines to end-users, thereby facilitating the efficient delivery of healthcare products.

2Distribution Network

CSP's distribution network is strategically designed to cover a wide geographic area within France. The company's main facility is located in Cournon-d'Auvergne, Auvergne, serving as a central hub for operations. Additionally, CSP operates multiple secondary establishments, including locations in Saint-Amant-Tallende and other regions, to enhance its logistical capabilities and ensure timely delivery of pharmaceutical products. (data-prospection.fr)

The company's logistics infrastructure is equipped to handle a diverse range of pharmaceutical products, including finished formulations such as tablets, capsules, syrups, and injections. This capability underscores CSP's commitment to maintaining a robust and efficient distribution network that meets the needs of healthcare providers throughout France.

3Industry Role

In France's pharmaceutical supply chain, CSP functions primarily as a wholesaler and distributor. The company is responsible for sourcing pharmaceutical products from various manufacturers, including those based in India, and ensuring their distribution to healthcare professionals and institutions across the country. This role is critical in maintaining the flow of pharmaceutical goods from producers to end-users, thereby supporting the healthcare system's operational efficiency.

CSP's operations also involve managing the complexities associated with importing pharmaceutical products, including compliance with regulatory requirements and maintaining quality standards. By fulfilling these responsibilities, CSP contributes significantly to the accessibility and availability of pharmaceutical products in the French market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Centre Specialites Pharmaceutiques

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

CSP's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, CSP imported finished pharmaceutical formulations totaling $7.3 million USD from India, encompassing 158 shipments and 869 unique formulations. The top five products imported include Metformin ($5.9 million, 1.3% share), Diclofenac ($1.3 million, 0.4% share), and Atenolol ($100,000, 0.2% share).

The supplier base from India is diverse, comprising eight unique suppliers. The largest supplier, Micro Labs Limited, accounted for 74.6% of the total import value, followed by Zydus Lifesciences Limited (14.8%) and Cadila Healthcare Limited (7.7%). This distribution indicates a strategic choice by CSP to establish strong partnerships with key Indian pharmaceutical manufacturers.

While the concentration on a few suppliers may offer benefits such as streamlined logistics and potentially favorable pricing, it also introduces risks associated with over-reliance on specific sources. Any disruptions in the supply chain from these suppliers could impact CSP's ability to meet market demand. Therefore, CSP's sourcing strategy reflects a balance between leveraging established supplier relationships and managing potential supply chain vulnerabilities.

2Supply Chain Resilience

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing the pharmaceutical sector is the Agence nationale de sécurité du médicament et des produits de santé (ANSM). ANSM is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products available in the French market. The regulatory framework governing pharmaceutical imports includes compliance with the French Public Health Code, which outlines the requirements for manufacturing, importing, and distributing medicinal products.

For Indian pharmaceutical manufacturers exporting to France, obtaining a Certificate of Compliance with Good Manufacturing Practices (GMP) is essential. This certificate, recognized by ANSM, attests that the manufacturing facilities adhere to the quality standards set forth by the European Union. Additionally, products must undergo batch testing and meet stability requirements to ensure their safety and efficacy upon reaching the French market.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in France are stringent. Indian exporters must obtain an import license from ANSM, which involves demonstrating compliance with EU GMP standards. This process includes providing evidence of quality control measures, manufacturing processes, and product testing protocols. Recognition of GMP certificates from reputable authorities, such as the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S), can facilitate the approval process.

Centre Specialites Pharmaceutiques — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

CSP's product strategy focuses on therapeutic areas with high demand in the French market, particularly in the categories of Diabetes & Endocrine, Analgesics & Antipyretics, and Cardiovascular. The company's imports from India reflect this focus, with Metformin, Diclofenac, and Atenolol being among the top imported products. This strategic selection aligns with the prevalent health concerns in France, where chronic conditions such as diabetes, pain management, and cardiovascular diseases are significant public health issues.

By concentrating on these therapeutic areas, CSP aims to meet the needs of healthcare providers and patients, ensuring the availability of essential medications. The company's sourcing decisions are driven by market demand, regulatory considerations, and the goal of providing high-quality pharmaceutical products to the French market.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Centre Specialites Pharmaceutiques

What products does Centre Specialites Pharmaceutiques import from India?

Centre Specialites Pharmaceutiques imports 3 pharmaceutical products across 3 categories. Top imports: Metformin ($5.9M), Diclofenac ($1.3M), Atenolol ($100.0K).

Who supplies pharmaceuticals to Centre Specialites Pharmaceutiques from India?

Centre Specialites Pharmaceutiques sources from 8 verified Indian suppliers. The primary supplier is Micro Labs Limited (74.6% of imports, $19.5M).

What is Centre Specialites Pharmaceutiques's total pharmaceutical import value?

Centre Specialites Pharmaceutiques's total pharmaceutical import value from India is $7.3M, based on 158 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Centre Specialites Pharmaceutiques focus on?

Centre Specialites Pharmaceutiques imports across 3 categories. The largest: Diabetes & Endocrine (80.8%), Analgesics & Antipyretics (17.8%), Cardiovascular (1.4%).

Get Full Centre Specialites Pharmaceutiques Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.